Switch theme
Sign up to access all valuation multiples
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The company's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, OB318, and others. Along with its subsidiaries, the company operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation segment.
2008
n/a
Last FY Revenue $3.9M
Last FY EBITDA -$22.9M
$721M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Oneness Biotech achieved revenue of $3.9M and an EBITDA of -$22.9M.
Oneness Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oneness Biotech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $2.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 53% | XXX | XXX | XXX |
| EBITDA | XXX | -$22.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -581% | XXX | XXX | XXX |
| EBIT | XXX | -$36.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -920% | XXX | XXX | XXX |
| Net Profit | XXX | -$38.9M | XXX | XXX | XXX |
| Net Margin | XXX | -988% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oneness Biotech's stock price is TWD 59 (or $2).
Oneness Biotech has current market cap of TWD 28.0B (or $933M), and EV of TWD 21.6B (or $721M).
See Oneness Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $721M | $933M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oneness Biotech has market cap of $933M and EV of $721M.
Oneness Biotech's trades at 183.3x EV/Revenue multiple, and -31.5x EV/EBITDA.
Equity research analysts estimate Oneness Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oneness Biotech's P/E ratio is not available.
See valuation multiples for Oneness Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $933M | XXX | $933M | XXX | XXX | XXX |
| EV (current) | $721M | XXX | $721M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 183.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -31.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -19.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -24.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -54.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOneness Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Oneness Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oneness Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oneness Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -581% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 784% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 974% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oneness Biotech acquired XXX companies to date.
Last acquisition by Oneness Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Oneness Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oneness Biotech founded? | Oneness Biotech was founded in 2008. |
| Where is Oneness Biotech headquartered? | Oneness Biotech is headquartered in Taiwan. |
| Is Oneness Biotech publicy listed? | Yes, Oneness Biotech is a public company listed on ROCO. |
| What is the stock symbol of Oneness Biotech? | Oneness Biotech trades under 4743 ticker. |
| When did Oneness Biotech go public? | Oneness Biotech went public in 2011. |
| Who are competitors of Oneness Biotech? | Similar companies to Oneness Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oneness Biotech? | Oneness Biotech's current market cap is $933M |
| Is Oneness Biotech profitable? | Yes, Oneness Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
